Drugmakers shun FDA pilot program on drug names

10/13/2011 | Pharmalot.com

The FDA asked drugmakers to participate in a pilot program designed to reduce errors caused by similarly named drugs. Three drugmakers registered for the program during the past two years, and only one submitted a complete application.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY